Knott David M Jr holds a focused book of 84 stocks worth $189.2M as of Q2 2026 (disclosed Aug 12, 2026, a ~43-day 13F lag). This quarter they opened Catalyst Bancorp Inc and trimmed JPMorgan Chase & Co. Their largest long position is Alphabet Inc-CL C at 17% of the equity book. Cloning the disclosed picks since 2024 would be +39% (+20.9%/yr). That is a simulation of the disclosed long book, not audited returns.
The reported book (valued from quarter-end) returned +70.3%, a 31.0-point gap that is the cost of the ~43-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning Knott David M Jr's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~43 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
92% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Knott David M Jr
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 78 / 80 | $88.9B |
| MORGAN STANLEY | 76 / 80 | $361.5B |
| CITIGROUP INC | 75 / 80 | $39.0B |
| BlackRock, Inc. | 74 / 80 | $1.6T |
| Tower Research Capital LLC (TRC) | 74 / 80 | $584.3M |
| GOLDMAN SACHS GROUP INC | 73 / 80 | $164.7B |
| ROYAL BANK OF CANADA | 73 / 80 | $108.1B |
| Ken Griffin | 73 / 80 | $15.1B |
Ranked by how many of Knott David M Jr's top 80 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Alphabet Inc-Cl C Common | $32.3M | 91.4K | 17.1% | —Held | |
| 2 | Apollo Global Management, Inc. Common | $26.6M | 225.0K | 14.1% | —Held | |
| 3 | Syndax Pharmaceutical, Inc. Common | $9.6M | 437.2K | 5.1% | ▲+3.6% Added · +15K sh | |
| 4 | Xeris Biopharma Holdings, Inc. Common | $8.4M | 1.06M | 4.4% | —Held | |
| 5 | Travere Therapeutics, Inc. Common | $8.4M | 147.3K | 4.4% | ▲+4.7% Added · +7K sh | |
| 6 | Protagonist Therapeutics, Inc Common | $7.7M | 63.0K | 4.1% | —Held | |
| 7 | Bridgebio Pharma, Inc. Common | $6.9M | 92.8K | 3.7% | ▲+3.2% Added · +3K sh | |
| 8 | Iovance Biotherapeutics, Inc. Common | $6.7M | 1.60M | 3.5% | —Held | |
| 9 | Alkermes PLC Common | $6.4M | 121.8K | 3.4% | ▲+1.5% Added · +2K sh | |
| 10 | JPMorgan Chase & Co. Common | $5.9M | 18.1K | 3.1% | ▼−7.1% Reduced · −1K sh | |
| 11 | Janus Henderson AAA CLO ETF Common | $4.7M | 93.5K | 2.5% | —Held | |
| 12 | LPL Financial Holdings Inc. Common | $4.6M | 16.5K | 2.5% | —Held | |
| 13 | Cogent Biosciences Inc. Common | $4.3M | 111.1K | 2.3% | ▲+6.8% Added · +7K sh | |
| 14 | TG Therapeutics, Inc. Common | $3.7M | 66.8K | 1.9% | ▼−26% Reduced · −23K sh | |
| 15 | Catalyst Pharmaceuticals, Inc. Common | $3.6M | 114.0K | 1.9% | ▲New New position | |
| 16 | Agios Pharmaceutical, Inc. Common | $3.5M | 95.1K | 1.9% | ▲+2.1% Added · +2K sh | |
| 17 | Viridian Therapeutics, Inc. Common | $3.3M | 181.0K | 1.8% | —Held | |
| 18 | Relmada Therapeutics, Inc. Common | $3.1M | 451.0K | 1.6% | ▲+2.7% Added · +12K sh | |
| 19 | Arcus Biosciences, Inc. Common | $2.5M | 81.2K | 1.3% | —Held | |
| 20 | Cybin Inc Common | $2.4M | 370.0K | 1.3% | ▲+5.7% Added · +20K sh | |
| 21 | SPDR S&P Biotech ETF Common | $2.4M | 15.0K | 1.3% | —Held | |
| 22 | Rezolute, Inc. Common | $1.9M | 370.0K | 1.0% | —Held | |
| 23 | AllianceBernstein Holding L.P. Common | $1.7M | 48.0K | 0.9% | —Held | |
| 24 | Madrigal Pharmaaceuticals, Inc. Common | $1.6M | 3.0K | 0.9% | ▲+50% Added · +1K sh | |
| 25 | AtriCure, Inc. Common | $1.4M | 51.4K | 0.8% | —Held | |
| 26 | DocGo, Inc. Common | $1.4M | 2.67M | 0.7% | —Held | |
| 27 | Ardelyx, Inc. Common | $1.3M | 263.2K | 0.7% | ▲+27% Added · +56K sh | |
| 28 | Ultragenyx Pharmaceutical Inc. Common | $1.3M | 38.1K | 0.7% | ▲+15% Added · +5K sh | |
| 29 | The Panagram BBB-B CLO ETF Common | $1.3M | 47.8K | 0.7% | —Held | |
| 30 | Cullinan Therapeutics, Inc. Common | $1.3M | 69.2K | 0.7% | ▲+186% Added · +45K sh | |
| 31 | Johnson & Johnson Common | $1.3M | 4.9K | 0.7% | —Held | |
| 32 | Vera Therapeutics, Inc. Common | $1.1M | 26.0K | 0.6% | —Held | |
| 33 | Orchestra Biomed Holdings, Inc. Common | $1.1M | 253.7K | 0.6% | —Held | |
| 34 | Spruce Biosciences, Inc. Common | $1.1M | 20.0K | 0.6% | ▲New New position | |
| 35 | Connect Biopharma Holdings Limited Common | $1.1M | 444.9K | 0.6% | ▲+15% Added · +57K sh | |
| 36 | iShares Biotechnology ETF Common | $1.0M | 5.5K | 0.6% | —Held | |
| 37 | Biogen Inc. Common | $864K | 4.0K | 0.5% | —Held | |
| 38 | Pfizer Inc. Common | $779K | 32.3K | 0.4% | —Held | |
| 39 | Apple Inc. Common | $722K | 2.5K | 0.4% | —Held | |
| 40 | Canadian Natural Resources Limited Common | $664K | 16.8K | 0.4% | —Held | |
| 41 | Pelthos Therapeutics, Inc. Common | $624K | 22.1K | 0.3% | ▲+4.7% Added · +1K sh | |
| 42 | International Business Machines Common | $602K | 2.1K | 0.3% | —Held | |
| 43 | Microsoft Corporation Common | $597K | 1.6K | 0.3% | —Held | |
| 44 | Verastem Inc. Common | $592K | 155.0K | 0.3% | ▲+49% Added · +51K sh | |
| 45 | Kura Oncology, Inc. Common | $579K | 52.8K | 0.3% | —Held | |
| 46 | Solid Bioscience Inc. Common | $562K | 56.2K | 0.3% | ▲+19% Added · +9K sh | |
| 47 | DuPont de Nemours, Inc. Common | $511K | 3.8K | 0.3% | ▲New New position | |
| 48 | Insmed Incorporated Common | $453K | 4.3K | 0.2% | ▲New New position | |
| 49 | LB Pharmaceuticals, Inc. Common | $421K | 13.0K | 0.2% | ▲New New position | |
| 50 | CareDx, Inc. Common | $388K | 13.6K | 0.2% | ▲New New position |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1892770/holdings"
Use Arkolith to show Knott David M Jr's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 12, 2026 | 86 | $189.2M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 14, 2026 | 88 | $168.0M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 12, 2026 | 91 | $215.9M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 12, 2025 | 92 | $248.0M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 11, 2025 | 89 | $220.6M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 12, 2025 | 88 | $212.0M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 12, 2025 | 93 | $276.5M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 13, 2024 | 99 | $284.6M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.